Quercetin
Quercetin scores 5.5 / 10 Neutral because bioavailability is poor, headline longevity and antiviral claims outpace human evidence, and the best replicated signals (allergic rhinitis, small BP reductions, uric acid) are narrow.
Quercetin scored 5.5 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Botanical Extract (non-adaptogenic).
What It Is
Quercetin is a plant flavonol found in onion, apple, capers, elderflower, tea, and Sophora japonica buds, and it is one of the most widely sold polyphenol supplements in the longevity and immune categories. Its Wikidata entry catalogs the molecule (3,3',4',5,7-pentahydroxyflavone) and its global use as a dietary supplement. The 5.5 Neutral score reflects an honest tension. Modern human evidence supports several narrow indications, especially allergic rhinitis on phytosome (Yamada 2022), small blood pressure reductions (Serban 2016), chronic prostatitis symptoms (Shoskes 1999), and a small uric acid drop (Shi 2016). The marketing language around longevity, COVID, MCAS, and senolytic stacks runs well ahead of those data.
Mechanistically, quercetin is a broad polyphenol with NF-kB inhibition, mast cell stabilization in cell models, antioxidant activity, mTOR modulation, and senolytic action on certain senescent-cell subtypes. It is the second half of the dasatinib plus quercetin senolytic protocol used in human pilots in IPF (Justice 2019) and diabetic kidney disease (Hickson 2019). The practical ceiling on every use case is bioavailability: plain quercetin aglycone or dihydrate is poorly absorbed, while quercetin phytosome (Riva 2019) and glucosylated forms (Liu 2025) raise plasma exposure by roughly 20 times.
Terminology
The most common confusion in quercetin marketing is that the molecule on the label may differ from the molecule that was studied, and the bioavailability difference between forms is large. Reading any quercetin claim without knowing the form, dose, glycoside profile, and trial design will mislead more often than it informs. The terms below appear repeatedly in the trial literature and on supplement labels, and they change how the evidence should be weighted.
- Aglycone: The free form of quercetin without an attached sugar. Poorly absorbed orally.
- Dihydrate: Aglycone crystallized with two water molecules. The cheapest, most common form on labels. Same poor absorption as aglycone.
- Phytosome: A lecithin (phosphatidylcholine) complex that raises plasma quercetin by roughly 20 times aglycone in healthy adults.
- Isoquercetin: Quercetin 3-O-glucoside. Glucosylated forms absorb better than aglycone or rutin.
- EMIQ: Alpha-glycosyl isoquercitrin. Enzymatically modified glucosylated quercetin with strong human PK data versus rutin and isoquercitrin.
- Rutin: Quercetin rutinoside. A historical capillary-fragility supplement, not interchangeable with quercetin.
- D plus Q: Dasatinib plus quercetin. The senolytic medical protocol; dasatinib is a prescription tyrosine kinase inhibitor.
- SASP: Senescence-Associated Secretory Phenotype. Inflammatory cytokine output from senescent cells; senolytic clearance is supposed to reduce SASP load.
- OATP1B1: A hepatic uptake transporter that handles statins such as pravastatin. Quercetin inhibition raises statin plasma exposure.
- P-glycoprotein: An efflux transporter that handles many drugs. Quercetin alters fexofenadine disposition in humans.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | Quercetin dihydrate (capsule, tablet, powder) | 500 to 1000 mg/day, split or single dose | 250 to 2000 mg/day |
| oral | Quercetin phytosome (lecithin complex) | 200 to 1000 mg/day | 200 to 1500 mg/day |
| oral | Isoquercetin or alpha-glycosyl isoquercitrin (EMIQ) | 100 to 500 mg/day | 100 to 1000 mg/day |
Protocols
Allergic rhinitis (phytosome) Clinical
- Dose
- 200 mg/day
- Frequency
- once daily
- Duration
- 4 weeks during allergy season
Based on Yamada 2022 RCT in 66 adults.
Blood pressure support Clinical
- Dose
- 500 to 730 mg/day
- Frequency
- once daily with meal
- Duration
- 4 to 12 weeks
Effect about 3 mmHg SBP, 2.6 mmHg DBP (Serban 2016).
Chronic prostatitis Clinical
- Dose
- 500 mg twice daily
- Frequency
- twice daily
- Duration
- 1 month
Shoskes 1999 RCT, 67 percent responders versus 20 percent placebo.
D plus Q senolytic (medical only) Clinical
- Dose
- 1000 to 1250 mg quercetin plus dasatinib 100 mg
- Frequency
- 2 to 3 consecutive days, intermittent
- Duration
- single cycle or repeated under supervision
Requires prescription dasatinib and clinician oversight.
How this score is calculated →
Upside contribution: 1.83
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.6 | 0.650 | |
| Breadth of Benefits | 15% | 3.4 | 0.510 | |
| Evidence Quality | 25% | 2.6 | 0.650 | |
| Speed of Onset | 10% | 3.0 | 0.300 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality Upside | 15% | 3.6 | 0.540 | |
| Total | 2.830 |
Upside Rationale
The strongest upside comes from a tight cluster of narrow, replicated human signals. Allergic rhinitis on phytosome, small blood pressure reductions across meta-analyses, chronic prostatitis symptom relief, and a small uric acid drop carry the bulk of the human evidence base. The senolytic narrative depends on dasatinib plus quercetin pilots, not on quercetin alone, and should be treated as a medical protocol rather than as an OTC supplement claim. Bioavailability constrains every use case, and the upside score reflects that practical ceiling more than mechanistic breadth.
Efficacy (2.6/5.0): The strongest single human result is Serban 2016 meta-analysis of 7 RCTs (n=587) showing SBP down 3.04 mmHg and DBP down 2.63 mmHg, strongest at 500 mg/day or higher. Yamada 2022 randomized 66 adults to 200 mg/day quercetin phytosome for 4 weeks and reported consistent improvements in eye itching, sneezing, nasal discharge, sleep disturbance, and visual analogue symptoms. Shoskes 1999 chronic prostatitis RCT in 30 men showed 67 percent responders versus 20 percent placebo on NIH symptom score. Shi 2016 lowered uric acid by 26.5 micromol per liter. D plus Q pilots reduced senescence markers (Hickson 2019) but quercetin alone is not proven senolytic.
Breadth of Benefits (3.4/5.0): Quercetin touches many systems with at least suggestive human data. Cardiovascular has the BP meta-analyses plus the flavonol cohorts (Hertog 1993). Immune and respiratory carry the allergy and COVID-adjacent signals. Urology has the prostatitis trial. Metabolic has the small insulin signal in Arabi 2023. Coagulation has the isoquercetin oncology data (Zwicker 2019), although that should not be attributed to quercetin aglycone. Mechanistic breadth is broader than clinical breadth. Many systems score 1.0 to 2.0 because they lack adequate human evidence.
Evidence Quality (2.6/5.0): There are multiple RCTs and meta-analyses, but the corpus is uneven. The BP meta-analyses and the bioavailability comparisons are the most defensible Tier 1 to 2 evidence. Several COVID and senolytic trials are open-label, small, or multicomponent. Nieman 2010 is the largest community URTI RCT and was null overall. Cochrane has not produced a quercetin-specific systematic review at the indication level. Industry-adjacent phytosome trials need cautious reading. Evidence quality should not rise above moderate until larger blinded trials confirm formulation-specific results.
Speed of Onset (3.0/5.0): Allergy symptom and COVID symptom endpoints can move within days to weeks. BP and uric acid show effects within 2 to 4 weeks across the relevant trials. Senescence-marker changes appeared by day 11 in the small D plus Q pilot (Hickson 2019), but those are biomarker shifts and not clinical outcomes. Slower or unproven endpoints include longevity, healthspan, cognition, and broad inflammation. Onset is fast for the narrow indications where evidence exists and undefined elsewhere.
Durability (1.8/5.0): Most trials run 2 to 12 weeks. There is little human evidence that benefits persist after stopping, and most polyphenol effects appear to fade with washout. Senolytic cycling is unvalidated for long-term outcomes. The flavonol cohort signals come from long-term food intake, not from supplementation cycles. Durability is a real weakness of the supplement framing.
Bioindividuality Upside (3.6/5.0): Response likely depends on form, gut metabolism, UGT and SULT handling, baseline inflammation, medication stack, disease state, and whether the user takes aglycone, phytosome, EMIQ, isoquercetin, or D plus Q. Allergic rhinitis sufferers, prehypertensive adults, hyperuricemic adults, and older inflamed adults are the most plausible strong responders. Cognitive, mood, and athletic populations are weak responders in the available data. Use bioindividuality to target the molecule rather than to defend broad claims.
Downside contribution: 1.30 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.4 | 0.720 | |
| Side Effect Profile | 15% | 2.0 | 0.300 | |
| Financial Cost | 5% | 2.2 | 0.110 | |
| Time/Effort Burden | 5% | 1.6 | 0.080 | |
| Opportunity Cost | 5% | 2.7 | 0.135 | |
| Dependency / Withdrawal | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 1.975 | |||
| Harm subtotal × 1.4 | 2.310 | |||
| Opportunity subtotal × 1.0 | 0.325 | |||
| Combined downside | 2.635 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.295 |
Downside Rationale
The dominant downside cluster is interaction risk plus opportunity cost. Short-term oral quercetin up to about 1000 mg/day is reasonably tolerated, but warfarin and antiplatelet stacks, statin uptake via OATP1B1, P-glycoprotein substrates, narrow therapeutic index medications, chemotherapy, and dasatinib protocols carry real interaction risk. The opportunity cost of relying on quercetin for COVID, MCAS, cancer, H pylori, or broad longevity instead of proven care is the most consequential downside. Intrinsic short-term safety is mild for most adults.
Safety Risk (2.4/5.0): No catastrophic intrinsic adverse event signal at usual oral doses (Andres 2018). Warfarin has a case-report enhanced anticoagulation signal (Choi 2022). Pravastatin AUC rose 24 percent and Cmax 31 percent on quercetin 500 mg/day for 14 days via OATP1B1 (Wu 2012). P-glycoprotein effects appeared in a fexofenadine probe (Wang 2009). CYP1A2, CYP2A6, NAT2, and xanthine oxidase markers shifted in a caffeine probe (Ahn 2009), although broad clinically dangerous CYP inhibition is not established. IV high-dose quercetin produced renal toxicity in a phase 1 oncology setting (Ferry 1996). Pregnancy and pediatric safety data are inadequate.
Side Effect Profile (2.0/5.0): Oral side effects are mild for most adults. GI upset, headache, and intolerance appear in a minority across the RCTs. The Farr and Hickson D plus Q trials reported events tied to dasatinib rather than to quercetin alone. High-dose long-term use above 12 weeks lacks adequate safety data (Andres 2018). EMIQ, phytosome, and isoquercetin do not appear to add unique side effects beyond aglycone. Form choice should be driven by absorption and indication, not by side-effect tolerance.
Financial Cost (2.2/5.0): Plain quercetin dihydrate is cheap. Phytosome, EMIQ, and isoquercetin run higher at roughly $20 to $50 per month at study-dose ranges. Quality control across brands is variable and labels often mix forms without dose-equivalent clarity. Cost is moderate compared with pharmaceuticals or devices and should not drive the decision.
Time/Effort Burden (1.6/5.0): Oral dosing is simple. The main effort cost is choosing the right form, matching the dose to the indication, and avoiding unsupported liposomal or combo claims. Cycling is not required outside D plus Q. Total administration time is minimal.
Opportunity Cost (2.7/5.0): The largest practical downside. Users who rely on quercetin for COVID, cancer, MCAS, H pylori, or broad longevity may delay proven care. For allergic rhinitis, BP support, prostatitis, or uric acid management, the opportunity cost is low. For senolytic ambitions, D plus Q remains a medical protocol and dasatinib carries a different risk profile entirely.
Dependency/Withdrawal (1.2/5.0): No addiction or physiologic dependency signal. Benefits, if present, likely fade when stopping. No withdrawal syndrome is described in any trial.
Reversibility (1.8/5.0): Most oral side effects reverse on stopping. Interaction-driven harms, anticoagulation issues, dasatinib exposure during D plus Q, or delayed proven therapy can be less reversible. Track INR, creatinine, and ALT during higher-dose or polypharmacy use.
Verdict
The 5.5 Neutral score reflects honest tension between a wide mechanistic story and a narrow band of replicated human signals. Quercetin earns its supplement shelf space for allergic rhinitis on phytosome, small BP reductions, chronic prostatitis support, and hyperuricemia adjuncts. It does not earn the senolytic, antiviral, MCAS, cancer, H pylori, or broad longevity language used in much of the marketing. The form matters more than the dose: phytosome and glucosylated forms outperform plain dihydrate by roughly 20 times. The most consequential risks are interaction-mediated and opportunity-cost-driven rather than intrinsic toxicity.
✅ Best for: Adults with seasonal or perennial allergic rhinitis trying quercetin phytosome 200 mg/day during exposure windows. Prehypertensive or stage 1 hypertensive adults adding 500 to 730 mg/day quercetin alongside diet, exercise, and clinical monitoring. Men with chronic prostatitis or chronic pelvic pain syndrome trialing 500 mg twice daily for 1 month under urology guidance. Adults with elevated uric acid or gout history considering a 4-week quercetin trial alongside the standard urate-lowering and dietary approach. Older inflamed adults curious about senolytic-class exposure who lack prescription access to dasatinib and accept that quercetin alone is not proven senolytic.
❌ Avoid if: Pregnant, trying to conceive, or breastfeeding without clinician oversight; pediatric users outside a clinician-directed allergy protocol. On warfarin, DOACs, antiplatelets, transplant drugs, chemotherapy, or narrow therapeutic index medications without explicit review. On statins handled by OATP1B1 (especially pravastatin) where interaction can raise plasma drug exposure. On dasatinib or other tyrosine kinase inhibitors outside a clinician-supervised senolytic protocol. Substituting quercetin for proven care in COVID, cancer, H pylori, MCAS, or serious infection. Planned surgery or dental procedure within 2 weeks. Buying generic liposomal quercetin products without product-specific human PK data when phytosome or EMIQ alternatives exist.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cardiovascular: 5.8/10
Score: 5.8/10Quercetin lowers systolic BP by about 3.04 mmHg and diastolic BP by about 2.63 mmHg in the Serban 2016 meta-analysis of 7 RCTs (n=587), with effects strongest at doses 500 mg/day or higher. The Popiolek-Kalisz 2022 update confirms small BP signals. Stage 1 hypertensives saw clearer reductions in Edwards 2007 at 730 mg/day for 28 days. Flavonol-rich cohorts in Hertog 1993 inversely associate with CHD mortality, but event reduction is unproven. The Arabi 2023 umbrella review found no consistent lipid, FBG, or HOMA-IR signal.
Cellular Senescence: 5.3/10
Score: 5.3/10Dasatinib plus quercetin reduced adipose and skin senescent-cell markers and SASP factors in 9 diabetic kidney disease patients within 11 days (Hickson 2019). Justice 2019 showed feasibility in IPF (n=14) with improved physical function. Nambiar 2023 was a phase 1 single-blind IPF pilot (n=12) with no meaningful signal on frailty or pulmonary function. Farr 2024 phase 2 intermittent D plus Q in postmenopausal women (n=60) was null on bone turnover overall, with an exploratory high p16 tertile signal. Quercetin alone is not proven senolytic in humans.
Anti-Inflammatory: 5.0/10
Score: 5.0/10Meta-analysis of human trials by Ou 2020 found no overall effect on CRP, IL-6, or TNF-alpha, with subgroup signals only. Disease-specific signals exist, including reductions in oxidative stress and inflammatory markers in sarcoidosis (Boots 2011) and downstream symptom benefits in allergic rhinitis. Mechanistic anti-inflammatory pathways via NF-kB and NLRP3 are well documented preclinically. Translation to systemic inflammation markers in healthy adults is inconsistent. The score reflects clear mechanism plus modest disease-specific human signals offset by null overall biomarker effects.
Chronic Pain Management: 5.0/10
Score: 5.0/10Shoskes 1999 randomized 30 men with chronic prostatitis or chronic pelvic pain syndrome to 500 mg quercetin twice daily for 1 month, with 67 percent responding versus 20 percent on placebo by NIH symptom score. This is the strongest chronic pain RCT in the quercetin literature, but it is narrow and small. Broader chronic pain claims for fibromyalgia, low back pain, or general musculoskeletal pain are not supported by adequately powered RCTs. The IPF Justice 2019 protocol used D plus Q and reported physical function shifts, which is adjacent but not chronic pain proper.
Respiratory: 5.0/10
Score: 5.0/10Early COVID and IPF signals exist but are mostly open-label or small. Di Pierro 2021 reported lower hospitalization with 1000 mg/day quercetin phytosome in 152 outpatients. Di Pierro 2022 improved day 7 PCR negativity in 100 outpatients. Justice 2019 IPF feasibility used D plus Q rather than quercetin alone, and pulmonary function did not change. Brandao 2024 cultured lung cells showed reduced ACE2 and TMPRSS2 but no reduction in SARS-CoV-2 infection. The respiratory score reflects suggestive symptom data, not robust outcomes.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Immune Function Primary | 4.8 | The Nieman 2010 community URTI RCT in 1002 adults was null overall, with a subgroup signal only in fit adults over 40 at 1000 mg/day. COVID adjunct trials such as Di Pierro 2022 and the open-label pilots improved day 7 symptom and PCR endpoints, but blinding and sample sizes are limiting. Henson 2026 is a recent vaccine-response RCT worth tracking. Allergic immune effects are formulation-specific. Broad immune support claims outpace the data. |
| ○ Bone / Joint Health Primary | 4.2 | Farr 2024 phase 2 intermittent D plus Q in 60 postmenopausal women was null on the primary bone turnover endpoint overall. An exploratory high p16 tertile showed P1NP up 34 percent, CTx down 11 percent, and radius BMD up 2.7 percent. Maurer 2025 is preclinical chondrocyte and cartilage-tissue mechanism work, not clinical proof. The fisetin knee OA trial reported at ORS 2025 was not quercetin and was mixed. Quercetin-only bone or joint clinical evidence is weak. The score reflects narrow exploratory responder signals in a senolytic-class trial. |
| ○ Metabolic Health | 4.5 | The Arabi 2023 umbrella review of cardiometabolic meta-analyses found quercetin lowers SBP and insulin but does not affect DBP, lipids, inflammation, anthropometrics, FBG, or HOMA-IR consistently. Tamtaji 2019 in metabolic syndrome populations showed a small BP signal with limited metabolic consistency. The recent MASLD meta-analysis (Arslan 2025) suggests preliminary liver and lipid signal, but the study count and risk of bias still need scrutiny. Metabolic claims should be limited to specific subgroups, not broad insulin-sensitization or lipid-lowering claims. |
| ○ Eye / Vision Health | 4.5 | Allergic eye symptom data come from EMIQ and phytosome trials. Yamada 2022 randomized 66 adults to 200 mg/day quercetin phytosome for 4 weeks, with improvements in eye itching, sneezing, nasal discharge, and visual analogue symptoms. Tosca 2025 is a pediatric multicomponent pilot. These results support symptomatic allergic eye benefits, not broad vision protection, retinal protection, glaucoma, or macular degeneration. Use the eye-vision rating as a narrow allergic-eye result and not as a general ophthalmic claim. |
| ○ Healthspan | 4.5 | Healthspan-relevant signals come from D plus Q pilots in IPF (Justice 2019) and diabetic kidney disease (Hickson 2019), plus the BP and uric acid effects of quercetin alone. Physical function improved in Justice 2019, although pulmonary function did not. Farr 2024 bone turnover was null overall. No long-window healthspan trial of quercetin alone has been published. The score reflects mechanistic plausibility plus several small disease-specific pilots, not durable outcome data. |
| ○ Antioxidant / Oxidative Stress | 4.5 | Strong chemistry and cell-level antioxidant signals are documented in Rice-Evans 1996 and Bors 1997. LDL oxidation by macrophages is inhibited in vitro (de Whalley 1990). Sarcoidosis users showed reductions in oxidative stress markers (Boots 2011). Translation to consistent reductions in F2-isoprostanes, oxidized LDL, or 8-OHdG in healthy adults is inconsistent across RCTs. In vitro radical-scavenging strength does not reliably translate to clinical antioxidant benefit, so the score is moderate not high. |
| ○ Longevity / Lifespan | 4.2 | Human longevity evidence rests on senolytic class pilots. Hickson 2019 reduced senescence markers in 11 days. Justice 2019 showed feasibility and physical function improvement in IPF. The bone trial Farr 2024 was null on bone turnover overall, with an exploratory responder subgroup. Flavonol cohorts such as Hertog 1993 suggest reduced CHD mortality but are confounded. No lifespan or all-cause mortality RCT exists for quercetin alone. D plus Q is dasatinib-dependent and should not be transferred to OTC quercetin products. |
| ○ Liver / Detoxification | 4.0 | The MASLD meta-analysis by Arslan 2025 suggests preliminary liver enzyme, lipid, and inflammation improvements with quercetin in MASLD adults, but the synthesis is new and study counts and bias profiles are still under review. No mainstream hepatology guideline endorses quercetin as MASLD therapy. Liver enzyme tracking is reasonable on higher-dose stacks. Claims of broad detoxification, glutathione boosting, or liver regeneration outpace human evidence. Treat the liver-detox rating as cautious-promising rather than as a confirmed therapeutic indication. |
| ○ Geriatric / Aging Population | 4.0 | Older-adult relevance comes through IPF, D plus Q, BP, and cohort signals such as Hertog 1993 and Nambiar 2023. Drug interaction concerns are amplified by polypharmacy and renal aging. Senolytic class pilots focus on older adults. The geriatric score reflects fit older adults with clear indications, not blanket supplementation for frail elderly users. |
| ○ Endurance / Cardio | 3.8 | A meta-analysis of 11 exercise studies in 254 adults by Kressler 2011 found a statistically significant but trivial 2 percent average endurance benefit, with high heterogeneity. Davis 2010 reported improved VO2max and endurance capacity in trained subjects, but Bigelman 2010 found no benefit in ROTC cadets at 1000 mg/day for 6 weeks. Scholten 2013 showed lower lipid peroxidation but no endurance gain. The endurance signal is real but small and inconsistent across populations and protocols. |
| ○ Body Composition / Fat Loss | 3.8 | Omi 2019 randomized 40 male athletes to EMIQ plus protein powder versus protein alone during resistance training and reported improved body composition. This is a small sports nutrition study and the effect is attributable to EMIQ plus protein, not to generic quercetin. Quercetin-rich onion-skin extracts in overweight prehypertensive adults supported vascular endpoints rather than fat-loss endpoints. No adequately powered weight-loss RCT for quercetin alone exists. Treat body composition gains as a possible niche signal in athletic populations using glucosylated forms. |
| ○ Kidney Function | 3.8 | Hickson 2019 used D plus Q in 9 diabetic kidney disease patients and reduced adipose and skin senescence markers within 11 days; clinical renal endpoints were not powered. Ferry 1996 phase 1 IV quercetin demonstrated renal toxicity at high IV doses, which informs a high-dose caution rather than a contraindication for moderate oral use. Oral quercetin has no human kidney-outcome RCT. Track creatinine and eGFR on high-dose or CKD users. The score reflects mechanism plus one D plus Q pilot, not durable renal benefit. |
| ○ VO2 Max | 3.5 | Davis 2010 reported VO2max gains in trained subjects on quercetin. Later RCTs in athletes were mixed, with Scholten 2013 and Bigelman 2010 both null on performance. The Kressler 2011 meta-analysis showed roughly 2 percent average benefit, mostly seen in untrained or moderately trained populations. The VO2max effect is inconsistent and small. Trained athletes should not expect a meaningful aerobic ceiling shift from quercetin alone. |
| ○ Strength / Power | 3.5 | Omi 2019 used EMIQ plus protein powder in 40 male athletes during resistance training and reported body composition benefits. Direct strength or power output evidence is thin. No quercetin-only resistance-training RCT showed meaningful gains in 1RM, peak power, or strength endurance. Treat strength claims as derivative of body composition rather than direct ergogenic. EMIQ and isoquercetin formulations are not interchangeable with quercetin dihydrate for athletic protocols. |
| ○ Blood Sugar / Glycemic Control | 3.3 | The Arabi 2023 umbrella review found no consistent effect on FBG or HOMA-IR, although insulin levels moved in some analyses. Shi 2016 reported no change in glucose despite a 26.5 micromol per liter drop in uric acid. Mechanistic alpha-glucosidase inhibition has been reported in vitro. Quercetin should not be marketed as a glycemic control intervention. Diabetes-relevant CKD users using D plus Q under supervision are a different category from general blood sugar support. |
| ○ Recovery / Repair | 3.2 | Antioxidant rationale supports a recovery hypothesis, but human data are limited. Scholten 2013 showed lower lipid peroxidation in distance runners without performance gains. Kressler 2011 found trivial average benefit across exercise studies. No high-quality DOMS, CK, or recovery-specific RCT supports a meaningful effect for quercetin alone. EMIQ plus protein populations are a special case. The score reflects mechanism plus inconsistent recovery readouts. |
| ○ Gut Health / Microbiome | 3.2 | Preclinical microbiome and barrier rationale exists, including modulation of tight junctions and short-chain fatty acid producers in rodent models. No adequately powered human microbiome or barrier endpoint trial confirms a direct gut benefit in healthy adults. Petersen 2016 shows food matrix and glycoside form alter absorption. Treat gut-health claims as mechanism-only until human endpoint data exist. |
| ○ Muscle Growth / Hypertrophy | 3.0 | Omi 2019 EMIQ plus protein in 40 male athletes showed body composition gains that may include lean mass context. Direct hypertrophy RCTs in resistance-trained adults are not available for quercetin alone. mTOR effects in cell models are mixed and do not support an anabolic claim. Muscle growth claims should not be made for generic quercetin dihydrate. |
| ○ Flexibility / Mobility | 3.0 | Justice 2019 reported physical function gains on D plus Q in IPF, including short physical performance battery improvements. Quercetin-only flexibility or mobility evidence is weak. Maurer 2025 is preclinical chondrocyte work and not clinical mobility proof. Treat flexibility and mobility gains as senolytic-class signals, not as quercetin-only benefits. |
Frequently Asked Questions
Does quercetin actually work?
Sometimes, for narrow indications. The best replicated signals are allergic rhinitis on phytosome 200 mg/day (Yamada 2022), small blood pressure reductions of about 3 mmHg SBP (Serban 2016), chronic prostatitis symptoms at 500 mg twice daily (Shoskes 1999), and a 26.5 micromol per liter uric acid drop (Shi 2016). Broad longevity, MCAS, cancer, and H pylori claims are not supported by adequate blinded RCTs.
Which form of quercetin is best absorbed?
Quercetin phytosome produces about 20 times higher plasma exposure than unformulated aglycone in healthy adults (Riva 2019, n=12). Liu 2025 reported quercetin-3-O-oligoglucosides about 20 times aglycone and fenugreek galactomannan plus lecithin encapsulation about 62 times aglycone. EMIQ absorbs better than isoquercitrin and rutin (Murota 2010). Liposomal claims need product-specific human PK data. Skip plain dihydrate when a phytosome or glucosylated form is available.
Is quercetin actually a senolytic?
Quercetin alone is not proven as a clinically meaningful senolytic. The senolytic data come from dasatinib plus quercetin (D plus Q) in 9 diabetic kidney disease patients (Hickson 2019) and 14 IPF patients (Justice 2019). Farr 2024 phase 2 D plus Q (n=60) was null on bone turnover overall. Dasatinib is a prescription drug. Treat D plus Q as a medical protocol, not as an OTC longevity stack.
Is quercetin safe with medications?
Short-term oral quercetin up to about 1000 mg/day is reasonably tolerated (Andres 2018). A warfarin case report showed enhanced anticoagulant effect (Choi 2022). Quercetin 500 mg/day for 14 days raised pravastatin AUC by 24 percent and Cmax by 31 percent (Wu 2012). P-glycoprotein effects appeared in a fexofenadine probe (Wang 2009). Anticoagulants, antiplatelets, statins, transplant drugs, and chemotherapy require clinician review.
Does quercetin help allergies or mast cell symptoms?
Allergic rhinitis has support. Yamada 2022 randomized 66 adults to 200 mg/day quercetin phytosome for 4 weeks and improved eye itching, sneezing, nasal discharge, sleep disturbance, and visual analogue symptoms. Tosca 2025 is a pediatric multicomponent pilot. Mast cell stabilization mechanisms are documented in cell models, but no MCAS or mastocytosis RCT confirms efficacy. Treat MCAS framing as extrapolation from allergic-rhinitis data plus mechanism, not as proven mast-cell disease therapy.
Should quercetin be used for COVID or viral infections?
COVID evidence is suggestive but not definitive. Di Pierro 2021 and Di Pierro 2022 reported faster symptom resolution in outpatients on quercetin phytosome, but trials were small and mostly open-label. Brandao 2024 cultured lung cells showed reduced ACE2 and TMPRSS2 but no reduction in SARS-CoV-2 infection. The community URTI RCT Nieman 2010 was null overall. Do not position quercetin as antiviral treatment.
What dose of quercetin is used in studies?
Common study doses include 200 mg/day phytosome for allergy (Yamada 2022), 500 to 730 mg/day for blood pressure or uric acid (Edwards 2007, Shi 2016), 500 mg twice daily for chronic prostatitis (Shoskes 1999), 500 to 1500 mg/day phytosome in COVID outpatient trials (Di Pierro 2022), and 1000 to 1250 mg quercetin with dasatinib in D plus Q protocols (Hickson 2019).
Quercetin phytosome vs plain dihydrate: which should I buy?
Phytosome wins on bioavailability. Riva 2019 showed about 20 times higher plasma exposure for phytosome versus unformulated. Liu 2025 confirms lipid complexation and glucosylation as the strongest bioavailability levers. Plain dihydrate is cheaper but most of an oral dose passes unabsorbed. EMIQ is the other reasonable choice when allergy or athletic protocols dominate. Avoid generic liposomal quercetin claims that lack product-specific human PK data. Match the form to the indication and dose.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible near-term mover is a larger blinded phytosome RCT in allergic rhinitis or early COVID outpatient care. A clean positive readout would push efficacy and evidence up and shift the score toward Worth Trying. Conversely, replicated null COVID trials or replicated null inflammation meta-analyses would pull the score toward Caution. D plus Q phase 2 and phase 3 readouts will reshape the cellular senescence subrating, but those results belong to the combined protocol, not quercetin alone. Bioavailability comparison trials and warfarin interaction case clusters round out the secondary movers.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Large blinded phytosome RCT in allergic rhinitis confirms Yamada 2022 | Efficacy 2.6 to 3.3, Evidence 2.6 to 3.2 | 6.4 / 10 Worth Trying |
| D plus Q phase 2 senolytic RCTs replicate Hickson 2019 and Justice 2019 signals in larger cohorts | Efficacy 2.6 to 3.0, Evidence 2.6 to 3.0 | 6.1 / 10 Worth Trying |
| Replicated null inflammation meta-analyses confirm Ou 2020 across larger samples | Efficacy 2.6 to 2.2, Evidence 2.6 to 2.3 | 4.8 / 10 Neutral |
| Replicated null COVID outpatient RCT contradicts Di Pierro 2022 in blinded design | Efficacy 2.6 to 2.2, Evidence 2.6 to 2.2 | 4.7 / 10 Caution |
| New warfarin or chemotherapy interaction cluster appears in pharmacovigilance | Safety 2.4 to 3.0, Reversibility 1.8 to 2.3 | 4.7 / 10 Caution |
| Phase 3 D plus Q senolytic RCT demonstrates a clinical outcome (frailty, healthspan) in older adults | Efficacy 2.6 to 3.6, Evidence 2.6 to 3.6 | 6.8 / 10 Worth Trying |
Key Evidence Sources
- Justice 2019 Pilot D+Q in IPF n=14 physical function gains, pulmonary function unchanged. First-in-human senolytic feasibility
- Hickson 2019 D+Q in diabetic kidney disease n=9 reduced senescence markers in 11 days. Adipose and skin senescence biomarker drop
- Farr 2024 Phase 2 intermittent D+Q in postmenopausal women n=60 null on bone turnover overall. Exploratory high p16 tertile responder signal
- Nambiar 2023 Phase 1 IPF D+Q pilot n=12 no signal on frailty or pulmonary function. Feasibility confirmed; efficacy not
- Di Pierro 2022 Early COVID outpatient RCT n=100 quercetin phytosome improved day 7 PCR negativity. Open-label limitation
- Di Pierro 2021 Early COVID outpatient open-label trial n=152 reported lower hospitalization. Quercetin phytosome 1000 mg/day
- Yamada 2022 Allergic rhinitis RCT n=66 quercetin phytosome 200 mg/day for 4 weeks. Improved eye itching, sneezing, nasal discharge, sleep disturbance
- Tosca 2025 Pediatric seasonal allergic rhinitis pilot quercetin phytosome plus zinc and vitamin C. Multicomponent; pediatric
- Serban 2016 Meta-analysis of 7 RCTs n=587 quercetin lowered SBP 3.04 mmHg and DBP 2.63 mmHg. Strongest BP signal at 500 mg/day or higher
- Popiolek-Kalisz 2022 Updated BP meta-analysis through May 2022. Confirms small BP effects
- Edwards 2007 Stage 1 hypertension RCT 730 mg/day quercetin for 28 days reduced BP. Population responder evidence
- Larson 2012 Acute BP reductions in hypertensive adults not explained by ACE or endothelin-1. Acute vascular signal
- Brull 2015 Onion skin extract crossover trial in overweight prehypertensive adults. Food-derived vascular signal
- Dower 2015 Quercetin-3-glucoside 160 mg/day crossover trial n=37 null on FMD and BP. Negative metabolic and vascular endpoints
- Arabi 2023 Umbrella review of cardiometabolic meta-analyses. Quercetin reduced SBP and insulin only
- Tamtaji 2019 Meta-analysis in metabolic syndrome and related disorders. Small BP signal
- Ou 2020 Meta-analysis of human inflammation trials no overall CRP IL-6 TNF effect. Subgroup signals only
- Boots 2011 Sarcoidosis trial reduced oxidative stress and inflammation markers. Small disease-specific antioxidant signal
- Kressler 2011 Meta-analysis of 11 exercise studies n=254 trivial endurance benefit. About 2 percent average
- Davis 2010 Quercetin increased VO2max and endurance capacity in a controlled trial. Later trials were mixed
- Bigelman 2010 Quercetin 1000 mg/day for 6 weeks did not improve performance in cadets. Negative ROTC trial
- Scholten 2013 Long-term quercetin reduced lipid peroxidation without endurance gain. Distance runners
- Omi 2019 EMIQ plus protein powder in male athletes improved body composition. Sports nutrition pilot
- Nieman 2010 Community URTI RCT n=1002 no overall benefit. Subgroup signal in fit adults over 40
- Henson 2026 COVID mRNA vaccine response RCT immune endpoint. Awaiting full-text mining
- Shi 2016 Crossover trial n=22 quercetin 500 mg/day lowered uric acid by 26.5 micromol per liter. No change in glucose or BP
- Shoskes 1999 Chronic prostatitis RCT n=30 quercetin 500 mg twice daily for 1 month. 67 percent responders versus 20 percent placebo
- Zwicker 2019 Isoquercetin in advanced cancer hypercoagulability n=57. D-dimer down 21.9 percent; not generic quercetin
- Ferry 1996 Phase I IV quercetin renal toxicity at high IV dose. Informs kidney caution at high doses
- Riva 2019 Crossover pharmacokinetic study n=12 phytosome about 20 times higher plasma. Strongest formulation PK reference
- Liu 2025 Systematic review and meta-analysis of human bioavailability through July 2024. Lipid complexation and glucosylation dominate
- Petersen 2016 Four-way crossover comparing apple matrices and quercetin dihydrate capsules. Food matrix matters
- Hollman 1995 Onion glycosides absorbed more than rutinoside or aglycone in ileostomy. Glycoside form matters
- Murota 2010 EMIQ absorbed better than isoquercitrin or rutin in human PK. EMIQ PK reference
- Arslan 2025 MASLD meta-analysis of RCTs preliminary liver and lipid signal. Recent; needs bias review
- Andres 2018 Safety review of oral quercetin up to about 1000 mg/day. Long-term high-dose data limited
- Choi 2022 Warfarin interaction case report enhanced anticoagulant effect. Anticoagulant caution
- Wang 2009 Fexofenadine probe data on P-glycoprotein interaction. Transporter interaction signal
- Wu 2012 Pravastatin AUC up 24 percent and Cmax up 31 percent on quercetin 500 mg/day for 14 days. OATP1B1 statin interaction
- Ahn 2009 Caffeine probe CYP1A2 2A6 NAT2 xanthine oxidase markers shifted. Enzyme markers; not broad CYP danger
- Bedada 2015 Midazolam probe no clear major CYP3A interaction. Liver CYP3A signal weak
- Poor 2017 Mechanistic warfarin work on albumin displacement plus CYP2C9 inhibition. Mechanism of warfarin interaction
- Brandao 2024 Cultured human lung cells lowered ACE2 and TMPRSS2 but did not reduce SARS-CoV-2. Mechanistic limitation for COVID claim
- Macready 2012 Community cognitive RCT no meaningful cognitive benefit. Cognition null
- Hertog 1993 Zutphen Elderly Study flavonoid intake inversely associated with CHD mortality. Observational cohort
- Maurer 2025 Human chondrocyte and cartilage tissue D plus Q preclinical OA mechanism. Preclinical only
- Rice-Evans 1996 Structure-activity antioxidant chemistry of flavonoids. Antioxidant chemistry foundation
- Bors 1997 Mechanistic antioxidant effects of flavonoids. Mechanism support
- de Whalley 1990 Flavonoids inhibited macrophage-mediated LDL oxidation in vitro. Cardiovascular mechanism
- NIH Office of Dietary Supplements 2024 COVID fact sheet on dietary supplements. Notes low oral bioavailability
- FDA 2026 Dietary supplements consumer update. Supplements are not pre-approved
- Knekt P et al 1996 - Flavonoid intake and coronary mortality in Finland: a cohort study.. Auto-resolved via strict PubMed lookup (author+year+topic match)
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Serban 2016, Yamada 2022, Di Pierro 2022, Shoskes 1999, Hickson 2019, Justice 2019, Riva 2019, Liu 2025
Pre-RCT-Era Pharmacology and Use
Confidence: Low
Citations: Rusznyak and Szent-Gyorgyi 1936, Griffith 1944, Hertog 1993, Knekt 1996, Keli 1996
Traditional Medicine Systems
Confidence: Limited
Citations: Chen 2010, EMA HMPC 2018, Elattar 2024, Annaz 2022, Jana 2010
Holistic Evidence for Quercetin
Modern RCTs, historical cohorts, and traditional plant use agree on a narrow band of plausibility: vascular tone, allergy and respiratory comfort, and digestive plant medicine. They diverge sharply on senolytic, antiviral, MCAS, cancer, and broad longevity claims, where only modern preclinical data support the marketing language.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- hs-CRP Baseline (pre-protocol) During | Expected Down
- Systolic Bp Baseline (pre-protocol) During | Expected Down
- Diastolic Bp During | Expected Down
- Uric Acid Baseline (pre-protocol) During | Expected Down
- ALT Baseline (pre-protocol) During | Expected Stable
- Creatinine Baseline (pre-protocol)
- eGFR During | Expected Stable
- Inr During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Watch | Secondary
- Sleep During | Expected Up | Tertiary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Nasal Congestion Scale 1-5 | During | Expected Down
- Sneezing Or Itchy Eyes Scale 1-5 | During | Expected Down
- Pelvic Pain Or Urinary Discomfort Scale 1-5 | During | Expected Down
- Bruising Or Bleeding Scale 1-5 | During | Expected Watch
- GI Upset Scale 1-5 | During | Expected Watch
- Medication Changes Scale text | During | Expected Watch
Red Flags: Stop and Consult
- Warfarin, DOAC, antiplatelet, chemotherapy, transplant drug, or narrow therapeutic index medication without clinician review
- Easy bruising, nosebleeds, black stools, or unusual bleeding
- New kidney pain, reduced urination, creatinine rise, or eGFR drop
- Pregnancy, trying to conceive, or breastfeeding without clinician review
- Planned surgery or dental procedure within 2 weeks
- Using dasatinib plus quercetin outside a clinician-supervised senolytic protocol
- Treating COVID, cancer, H pylori, MCAS, or serious infection with quercetin instead of proven care
Other interventions for Immune Function
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.830 − 1.295 = 0.535
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.535 / 5) × 5 = 5.5 / 10
